Compass share price: Medirest implements disinfection system at King’s College Hospital

on Dec 20, 2013
Updated: Oct 21, 2019
Listen

iNVEZZ.com, Friday, December 20: Compass Group Plc’s (LON:CPG) Medirest subsidiary has successfully introduced an innovative technology designed to eradicate infections at King’s College Hospital in London, the company announced in a press release earlier this week. The implementation of the disinfection system in the facility comes after an extensive 6-month trial and is part of an agreement between Medirest and Rapid Disinfection Services Ltd (RDS) to supply the innovative technology, called TRU-D UVC, to RDS NHS clients.

In today’s London trading, Compass shares were 0.6 percent higher at 937.00p as of 14:55 UTC. The shares have gained nearly 30 percent so far this year.
**First contract**
King’s College Hospital has become the first facility where Medirest’s new disinfection technology has been introduced on a permanent basis. Tru-D is designed to target and eradicate Healthcare Associated Infections (HCAIs), the company said, adding that it is the only mobile UV disinfection system to be capable of precisely calculating the correct UV dose required to remove pathogens from a specified environment. The device is fully automated and can be used in all spaces, the company said.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.

Steve Cenci, Managing Director of Medirest commented: “Pathogenic organisms are estimated to cost the NHS £1bn per year and we believe that by introducing this solution we can reduce this burden for Trusts and help facilitate better patient care.”


Jorge Sousa, Associate Director of Facilities at King’s College Hospital, described the implementation of the system as “very successful” and the device itself as quick and easy to use.
As part of the agreement with the RDS, Medirest, which provides catering and support services in the healthcare market, plans a wider roll-out of the product to medical facilities across the UK in the coming months.

The True-D technology has already been introduced in the US market, where it has been used successfully for over four years, the company said. The system is currently in operation in more than 100 hospitals in the country.
**As of 15:14 UTC buy Compass shares at 938.50p**
**As of 15:14 UTC sell Compass shares at 938.00p**
Trade stocks with Hargreaves Lansdown from £5.95 per deal.
Prices can go up and down meaning you can get back less than you invest. This is not advice. Dealing services provided by Hargreaves Lansdown.

Ad

Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals.

Learn more
Health & pharma Stock Market